Open AccessAbstract LB-309: Evaluation of ERG as a biomarker of responsiveness in a randomized trial of enzalutamide in combination with androgen deprivation in metastatic hormone sensitive prostate cancer
Author(s) -
Sreenivasa R. Chinni,
Ulka N. Vaishampayan,
Lance K. Heilbrun,
Louie Semaan,
Daryn Smith,
Dipenkumar Modi,
Paul Monk,
Shiela Tejwani,
Guru Sonpavde,
Kimberlee Dobson,
Brenda Dickow,
Elisabeth I. Heath,
Joseph A. Fontana,
Micheal L. Cher
Publication year - 2018
Publication title -
cancer research
Language(s) - English
Resource type - Conference proceedings
eISSN - 1538-7445
pISSN - 0008-5472
DOI - 10.1158/1538-7445.am2018-lb-309
Subject(s) - enzalutamide , prostate cancer , erg , medicine , bicalutamide , tmprss2 , oncology , androgen , prostate biopsy , androgen deprivation therapy , biopsy , cancer , urology , cancer research , androgen receptor , hormone , ophthalmology , retinal , disease , covid-19 , infectious disease (medical specialty)